Results 151 to 160 of about 207,765 (264)

LTB‐TREAT: A validated international prognostic model for time to treatment in low tumour burden follicular lymphoma

British Journal of Haematology, EarlyView.
LTB‐TREAT is a validated international prognostic model that identifies three groups of patients with distinct rates of time to treatment (TTT) in low tumour burden follicular lymphoma. The low‐risk group has a prolonged TTT with WW. The high‐risk group has early progression in whom treatment at diagnosis can be considered. Summary Watchful waiting (WW)
Luani Barge, Lachlan Webb, Anita Pelecanos, Niamh Waters, Ross Salvaris, Sam Lai, Tessa Potezny, Helen Cashman, Caitlyn Nguyen‐Ngo, Denise Lee, Costas K. Yannakou, Nada Hamad, Adrien Chauchet, Sylvain Choquet, Cédric Rossi, Adélie Herbin, Lukshe Kanagaratnam, Cyrielle Rodier, Constantine S. Tam, Abir Bhattacharyya, Chan Y. Cheah, Eliza A. Hawkes, Kirk Morris, Eric Durot, Joshua Tobin, Greg Hapgood   +25 more
wiley   +1 more source

Clinical periodontal diagnosis

Periodontology 2000, EarlyView., 2023
Abstract Periodontal diseases include pathological conditions elicited by the presence of bacterial biofilms leading to a host response. In the diagnostic process, clinical signs such as bleeding on probing, development of periodontal pockets and gingival recessions, furcation involvement and presence of radiographic bone loss should be assessed prior ...
Giovanni E. Salvi, Andrea Roccuzzo, Jean‐Claude Imber, Alexandra Stähli, Björn Klinge, Niklaus P. Lang   +5 more
wiley   +1 more source

<i>Ascaris Lumbricoides</i> through an Intercostal Chest Tube in A Case with Hodgkin's Lymphoma. [PDF]

Eur J Case Rep Intern Med
Öz A, Aydın S.
europepmc   +1 more source

Primary multifocal osseous Hodgkin's lymphoma with spinal involvement. [PDF]

Oxf Med Case Reports
Nathani NNA, Kumari L, Ali N.
europepmc   +1 more source

Long‐term results of brentuximab vedotin and bendamustine for first‐line treatment of Hodgkin lymphoma in the elderly (HALO trial)

British Journal of Haematology, EarlyView.
Summary The Hodgkin lymphoma treatment in the elderly (eHL) is a challenge due to a narrow therapeutic window between therapy effectiveness and toxicity. Both bendamustine (Be) and brentuximab vedotin (BV) are well‐tolerated, effective drugs in relapsing HL, but no data exist on Be‐BV frontline treatment in eHL.
Andrea Gallamini, Simonetta Viviani, Davide Rapezzi, Caterina Patti, Pierre Feugier, Alessandro Rambaldi, Fontanet Bijou, Anna Borra, Cécile Borel, Tanguy Pace‐Loscos, Renaud Schiappa, Stephane Chauvie, Colin Debaigt, Anna Guidetti, Olivier Humbert, Jean‐Marc Schiano De Colella   +15 more
wiley   +1 more source

Non-Hodgkin's lymphoma presenting as a retroperitoneal mass in the emergency department: a case report. [PDF]

Front Med (Lausanne)
Liu T, Zhao Y, Cui L, Liu H, Qu F.
europepmc   +1 more source

BrECADD in three days: Implementation of a condensed intensive first‐line regimen in Hodgkin lymphoma

British Journal of Haematology, EarlyView.
BrECADD can be delivered over 3 days instead of four, reducing intravenous treatment days by 25% without compromising dose intensity. Among 30 patients with advanced‐stage Hodgkin lymphoma, no unexpected toxicity was observed; there were no early discontinuations, and 1‐year progression‐free and overall survival were both 100%.
Christian Peter Jaworek, Maja Supprian, Paul Jan Bröckelmann, Hishan Tharmaseelan, Justin Ferdinandus, Dennis A. Eichenauer, Anne Sophie Robertz, Janina Jablonski, Vincent Combüchen, Jan‐Oliver Staak, Karin Töpelt, Jan‐Michel Heger, Jon Rischewski, Jannik Stemler, Wolfram Klapper, Peter Borchmann, Bastian von Tresckow   +16 more
wiley   +1 more source

A Cardio-Obstetric Breakthrough Beyond Routine Pregnancy Care: Unmasking Hodgkin's Lymphoma. [PDF]

JACC Case Rep
Baig AS, Jawed S, Gurmani S, Bhatti S.
europepmc   +1 more source

How Hot Is Too Hot? Fever Thresholds for Initiating Antibiotics in Children With Haematological Malignancies

Acta Paediatrica, EarlyView.
C. S. V. Henriksen, U. Nygaard, G. Petersen, J. Brok, L. L. Hjalgrim, N. V. Vissing, M. B. Mønster   +6 more
wiley   +1 more source

SENIOR‐IPI: An easily applicable prognostic index for first‐line large B‐cell lymphomas patients >80 years treated with curative intent

British Journal of Haematology, EarlyView.
Summary Using LYmphoma Study Association clinical trials combining 438 first‐line large B‐cell lymphomas (LBCL) patients >80 years old, we defined SENIOR‐IPI, an easily applicable prognostic index for this elderly population treated with an anti‐CD20‐miniCHOP (cyclophosphamide, doxorubicin, vincristine and prednisone)‐based regimen.
Sydney Dubois, Fanny Cherblanc, Aurelien Belot, Lucie Oberic, Hervé Ghesquières, Corinne Haioun, Hervé Tilly, Jean‐Philippe Jais, Fabrice Jardin   +8 more
wiley   +1 more source